Electromed (ELMD) just posted Q3 2026 results with revenue of US$18.6 million and basic EPS of US$0.37, alongside trailing twelve month revenue of US$71.8 million and EPS of US$1.22 that sit against a 41.1% earnings growth rate over the past year. Over recent quarters the company has seen revenue move from US$15.7 million and EPS of US$0.22 in Q3 2025 to US$18.6 million and EPS of US$0.37 in Q3 2026, with trailing net profit margin at 14.1% compared with 11.7% a year earlier. This frames a profitability profile that investors will weigh against the current growth outlook.

See our full analysis for Electromed.

With the latest earnings context in place, the next step is to see how these revenue, EPS, and margin trends line up with the most widely shared narratives around Electromed and where those narratives might need updating.

TTM earnings of US$10.1 million back 41.1% growth story

• Over the last twelve months, Electromed generated US$71.8 million in revenue and US$10.1 million in net income, which lines up with the 41.1% year over year earnings growth figure already flagged.
• Consensus narrative expects earnings to reach US$14.4 million and margins of 15.4% over the next few years, and the current TTM margin of 14.1% sits in between that view and last year, which makes it useful context for judging how demanding those targets really are.
  • Analysts look for roughly 13.1% annual earnings growth and about 10.1% revenue growth, while the move from US$7.2 million to US$10.1 million in TTM net income over the past datasets shows the business already operating above that run rate.
  • With TTM EPS at US$1.22 versus the US$1.53 EPS level analysts reference for later years, you can see the gap investors are effectively paying for today rather than just relying on the latest quarter alone.

On these numbers, you are really comparing what the company has already earned with what analysts think it can sustainably earn a few years out, and that gap is what drives a lot of the debate around the stock. 📊 Read the what the Community is saying about Electromed.

Margins at 14.1% test the bullish efficiency story

• Trailing net profit margin sits at 14.1% compared with 11.7% a year earlier, alongside quarterly net income of US$3.0 million in Q3 2026 versus US$1.9 million in Q3 2025, which shows more profit per dollar of revenue on the recent data.
• Bulls argue that direct to patient focus, sales force leverage, and supply chain work can support long run margin strength, and the move from 11.7% to 14.1% provides some backing for that idea but also sets a higher bar for further improvement.
  • The bullish narrative talks about margins reaching 17.6%, so the current 14.1% margin and quarterly EPS path from US$0.22 in Q3 2025 to roughly US$0.37 in Q3 2026 suggest part of that story is already reflected in the trailing figures.
  • At the same time, the bullish case assumes revenue growth around 9.5% per year, and the TTM revenue path from about US$59.6 million to US$71.8 million shows solid expansion that investors can compare directly with those expectations.

Bulls are effectively saying the efficiency gains seen in these margins can continue, and the current profitability levels are the reference point for how much further that thesis needs to run. 🐂 Electromed Bull Case

P/E of 27.9x and US$34.03 price strain the bearish caution

• At a share price of US$34.03 and TTM EPS of US$1.22, Electromed trades on a P/E of 27.9x, above both the peer average of 13.6x and the US Medical Equipment industry on 24.1x, while the DCF fair value in the dataset is US$20.89.
• Bears highlight reliance on a single product and cost pressures as reasons this premium might be hard to justify, and the gap between the current share price and both peers and the DCF fair value gives that view clear numerical backing.
  • The DCF fair value of US$20.89 sits well below the US$34.03 market price, so anyone leaning toward the bearish narrative can point to that spread alongside the elevated P/E as a core valuation concern.
  • Even with the 33.8% five year earnings growth rate, critics argue that a P/E more than double the peer average leaves less room for execution missteps, given the business is still heavily centered around the SmartVest platform and the U.S. market.

For a more cautious take, the key question is whether this premium P/E and the DCF gap leave enough margin for error if growth or margins do not track the stronger recent history. 🐻 Electromed Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Electromed on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between bullish growth expectations and valuation caution, it helps to test the numbers yourself and decide where you stand. To see why some investors are optimistic about the company, take a closer look at its 2 key rewards.

See What Else Is Out There

Electromed’s premium P/E of 27.9x versus peers and the DCF fair value of US$20.89 highlights valuation pressure that could concern cautious investors.

If that pricing gap makes you uneasy, compare this setup with 46 high quality undervalued stocks so you can quickly focus on stocks where valuations look more forgiving right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.